Phaseline

Companies › UCB Biopharma SRL

UCB Biopharma SRL: clinical trials, targets and expected readouts

9 active drug programs in 30 registered trials: 14 Phase 3, 8 Phase 2, 6 Phase 1, 2 Phase 4; Neurology, Immunology, Other, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rozanolixizumab
IgG receptor FcRn large subunit p51 inhibitor
FCGRTPhase 4Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD); Generalized Myasthenia Gravis; Ocular Myasthenia GravisMay 2027
Bimekizumab
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis …Dec 2026
Alprazolam
GABA-A receptor; anion channel positive allosteric modulator
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 3Stereotypical Prolonged Seizures; Ophthalmology; Opioid Abuse; Drug InteractionsMar 2027
dapirolizumab pegol
CD40 ligand inhibitor
CD40LGPhase 3Systemic Lupus ErythematosusMay 2028
Brivaracetam
Synaptic vesicle glycoprotein 2A modulator
SV2APhase 3Childhood Absence Epilepsy; EpilepsyNov 2029
Zilucoplan
Complement C5 inhibitor
C5Phase 2Generalized Myasthenia Gravis; Healthy Participants; Generalized Myasthenia Gravis (gMG); Amyotrophic Lateral SclerosisMar 2027
Galvokimig (UCB9741)
Neutrophil elastase inhibitor
–Phase 2Atopic Dermatitis; Non-cystic Fibrosis Bronchiectasis; Chronic Obstructive Pulmonary Disease With Chronic BronchitisMay 2027
UCB5285–Phase 1Healthy ParticipantsDec 2026
Bepranemab (UCB0107)
Microtubule-associated protein tau inhibitor
MAPTPhase 1Progressive Supranuclear PalsyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06149559RozanolixizumabPhase 2Generalized Myasthenia GravisNeurologyOct 2026
NCT07286682UCB5285Phase 1Healthy ParticipantsOtherDec 2026
NCT05006079AlprazolamPhase 2Opioid AbusePsychiatryDec 2026
NCT06921850BimekizumabPhase 3Hidradenitis SuppurativaImmunologyDec 2026
NCT06506916BimekizumabPhase 3Moderate to Severe Plaque PsoriasisImmunologyMar 2027
NCT06961747ZilucoplanPhase 1Healthy ParticipantsOtherMar 2027
NCT05077904AlprazolamPhase 3Stereotypical Prolonged SeizuresNeurologyMar 2027
NCT05063162RozanolixizumabPhase 3Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)NeurologyMay 2027
NCT06055959ZilucoplanPhase 2Generalized Myasthenia GravisNeurologyMay 2027
NCT07277660Galvokimig (UCB9741)Phase 2Atopic DermatitisImmunologyMay 2027
NCT04297683ZilucoplanPhase 2Amyotrophic Lateral SclerosisNeurologyJul 2027
NCT06540144RozanolixizumabPhase 3Generalized Myasthenia GravisNeurologyOct 2027
NCT07246564RozanolixizumabPhase 4Myasthenia GravisNeurologyOct 2027
NCT07215949ZilucoplanPhase 3Generalized Myasthenia Gravis (gMG)NeurologyDec 2027
NCT04658199Bepranemab (UCB0107)Phase 1Progressive Supranuclear PalsyNeurologyDec 2027
NCT07219420BimekizumabPhase 3Palmoplantar PustulosisImmunologyDec 2027
NCT06874452AlprazolamPhase 4OphthalmologyOphthalmologyDec 2027
NCT06888193BimekizumabPhase 1Moderate to Severe Plaque PsoriasisImmunologyDec 2027
NCT06668181BimekizumabPhase 3Enthesitis-related ArthritisImmunologyApr 2028
NCT07290036BimekizumabPhase 1Psoriatic ArthritisImmunologyMay 2028
NCT06617325dapirolizumab pegolPhase 3Systemic Lupus ErythematosusImmunologyMay 2028
NCT06742333BimekizumabPhase 2PsoriasisImmunologyJul 2028
NCT06425549BimekizumabPhase 3Moderate to Severe Plaque PsoriasisImmunologyAug 2028
NCT07463521RozanolixizumabPhase 3Ocular Myasthenia GravisNeurologyDec 2028
NCT06757140AlprazolamPhase 1Drug InteractionsOtherJan 2029
NCT07720375Galvokimig (UCB9741)Phase 2Non-cystic Fibrosis BronchiectasisRespiratoryFeb 2029
NCT07725939Galvokimig (UCB9741)Phase 2Chronic Obstructive Pulmonary Disease With Chronic BronchitisRespiratoryJun 2029
NCT06315322BrivaracetamPhase 3Childhood Absence EpilepsyNeurologyNov 2029
NCT04715646BrivaracetamPhase 3EpilepsyNeurologyJul 2030
NCT07465289RozanolixizumabPhase 3Ocular Myasthenia GravisNeurologyMar 2031

Targets

CD40LG (1) FCGRT (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) IL17A (1) IL17F (1) C5 (1) SV2A (1) MAPT (1)

Companies with the same targets

Ono Pharmaceutical Lipocine Haisco Pharmaceutical Group SK Life Science Acacia Pharma Sedana Medical AbbVie Eledon Pharmaceuticals Amgen Johnson & Johnson (Janssen)

Companies built like this

Biogen H. Lundbeck SK Life Science Teva Branded Pharmaceutical Products R&D Pharming Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.